Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04775329

Primary Prophylaxis for Spontaneous Bacterial Peritonitis (SIBOC)

Primary Prophylaxis for Spontaneous Bacterial Peritonitis in Decompensated Chronic Liver Disease With Small Bowel Bacterial Overgrowth: A Randomised Trial

Sponsor: Changi General Hospital

Conditions Decompensated Cirrhosis Small Bowel Bacterial Overgrowth Syndrome

Interventions Rifaximin

Updated 4 times since 2021 Last updated: Jan 4, 2023 Started: Nov 1, 2020 Primary completion: Jan 1, 2023 Completion: Jan 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow recruitment and study closure

Other terminated trials from Changi General Hospital

See all terminations from Changi General Hospital

A PHASE2/PHASE3 clinical study on Decompensated Cirrhosis and Small Bowel Bacterial Overgrowth Syndrome, this trial is terminated or withdrawn. The trial is conducted by Changi General Hospital and has accumulated 4 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Feb 2023 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3

Status: Recruiting → Terminated
Mar 2021 — Feb 2023 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Changi General Hospital

Data source: Changi General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore